Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Asperger syndrome medical therapy
Introduction
Overview
Overview
Medical treatments used in Asperger Syndrome include: stimulants, a-2 adrenergic agonists, atypical antipsychotics, antidepressants and anticonvulsants.[1] Many studies believe that medications alone can not improve Asperger Syndrome’s (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
Medical Therapy
Medical Therapy
- Many studies believe that medications alone can not improve Asperger Syndrome’s (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
- Medications used in Asperger Syndrome (AS) include:[1]
- Stimulants such as methylphenidate and amphetamines (for comorbidity between AS and attention deficit hyperactivity disorder (ADHD))
- a-2 adrenergic agonists such as clonidine and guanfacine (treatment of aggression, anxiety and Tourette syndrome (TS) which are associated with AS)
- Atypical antipsychotics such as aripiprazole, olanzapine, ziprasidone (treatment of aggression, hallucinations, hyperactivity, irritability, anxiety, depression in AS patients)[2]
- Antidepressantssuch as selective serotonin reuptake inhibitors (SSRIs) (treatment of depressive disorders and obsessive compulsive disorder (OCD) associated with AS)
- Anticonvulsants(for aggression, mood disorders, irritability, repetitive behaviors in AS)[3]
References
References
- ↑ 1.0 1.1 1.2 1.3 Tarazi FI, Sahli ZT, Pleskow J, Mousa SA (2015). “Asperger’s syndrome: diagnosis, comorbidity and therapy”. Expert Rev Neurother. 15 (3): 281–93. doi:10.1586/14737175.2015.1009898. PMID 25655905.
- ↑ Crystal S, Olfson M, Huang C, Pincus H, Gerhard T (2009). “Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges”. Health Aff (Millwood). 28 (5): w770–81. doi:10.1377/hlthaff.28.5.w770. PMC 2896705. PMID 19622537.
- ↑ Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006). “Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder”. Int J Neuropsychopharmacol. 9 (2): 209–13. doi:10.1017/S1461145705005791. PMID 16316486.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]